Table 2.
Frequencies of the 3 outcome measures according to treatments and HR for the Cox regression models of time up to the event.
| Treatment | Survival |
Intubation |
Combined |
|||
|---|---|---|---|---|---|---|
| Fr/n (%) | HR (95% CI) significance | Fr/n (%) | HR (95% CI) significance | Fr/n (%) | HR (95% CI) significance | |
| Tocilizumab | 1/9 (11.1) | 1 | 1/6 (16.7) | 1 | 1/6 (16.7) | 1 |
| GC pulses | 5/60 (8.3) | 0.064 (0.03–1.181) | 3/60 (5) | 0.28 (0.019–4.19) | 8/60 (13.3) | 0.339 (0.032–3.64) |
| p = 0.065 | p = 0.356 | p = 0.372 | ||||
| GC pulses and tocilizumab | 1/23 (4.4) | 0.02 (0.0004–0.835) | 1 (4.4) | 0.24 (0.009–6.261) | 2/23 (8.7) | 0.175 (0.011–2.827) |
| p = 0.040 | p = 0.391 | p = 0.219 | ||||
Fr/n: frequencies by outcome; GC: glucocorticoids; HR: hazard ratio (risk ratio) estimated using the Cox proportional hazards model; CI: confidence interval.